Shire acquisition of Dyax

Charles River Associates medicine on money

In the US, a team of CRA consultants advised counsel to Shire on its acquisition of Dyax, a small pharmaceutical company with pipeline products to treat hereditary angioedema (HAE). The deal, reviewed by the FTC, closed with no divestitures.

Related capabilities

Meet our team